Donate

Shouxiong Huang, Ph.D.

University of Cincinnati
Finding a New TB Vaccine

Mycobacterium tuberculosis (Mtb) infects one-third of the world's population. Multidrug-resistant tuberculosis is present in virtually all countries, leading to an increased risk of failed antibiotic treatment. Development of novel TB vaccines is a global priority to fight tuberculosis. Although the licensed vaccine Bacillus Calmette-Guerin (BCG) has saved many children's lives, its protection against tuberculosis is insufficient. Previous vaccine development mainly focused on conventional T cells such as peptide-stimulated lymphocytes. We will target an unconventional T cell population, called mucosal-associated invariant T (MAIT) cells, which rapidly responds to other bacterial metabolites in early infection. We will determine mycobacterial metabolites for MAIT cell activation to facilitate the development of new TB vaccines.

Better Breather Club | Riverside Shore Memorial Hospital
Nassawadox, VA | Mar 26, 2020
Better Breather Club | Riverside Tappahannock Hospital
Tappahannock, VA | Mar 26, 2020